NASDAQ: VIR Vir Biotechnology, Inc. 10-Q

VIR closes $240M Astellas deal, raises $162M equity, advances ECLIPSE trials; CMO departs

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade VIR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.